Lidopen

Lidopen

Lidopen Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

EVERY EFFORT SHOULD BE MADE TO AVOID POSSIBLE INADVERTENT INTRAVASCULAR ADMINISTRATION THROUGH APPROPRIATE SELECTION OF INJECTION SITE SUCH AS THIGH OR DELTOID. DO NOT INJECT INTO BUTTOCK. Monitoring with an electrocardiograph is recommended when lidocaine hydrochloride is administered by the intramuscular route. In emergency situations when a ventricular rhythm disorder is suspected and electrocardiographic equipment is not available, a single dose may be administered when the physician in attendance has determined that the potential benefits outweigh the possible risks. If possible, emergency resuscitative equipment and drugs should be immediately available to manage potential adverse reactions involving the cardiovascular, respiratory, or central nervous system.

Occasional acceleration of ventricular rate may occur when lidocaine hydrochloride is administered to patients with atrial fibrillation.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Lidocaine hydrochloride is indicated in the management of cardiac arrhythmias, particularly those of ventricular origin, such as occur with acute myocardial infarction.

The selection of the intramuscular route of administration (single dose) is justified in the following circumstances:

  1. By a physician in whose opinion the potential benefits outweigh the possible risks even when ECG equipment is not available to verify the arrhythmia.
  2. By, or under the supervision of, a physician, including mobile coronary care units, when facilities for intravenous administration are not readily available, or under circumstances where maintaining continuous intravenous therapy is difficult or impossible.
  3. For use in the pre-hospital phase of suspected acute myocardial infarction by a patient who has transmitted his electrocardiogram with a CardioBeeper®, whose electrocardiogram demonstrates the presence of a ventricular arrhythmia and who is instructed by qualified medical personnel to self-administer the LidoPen® Auto-Injector.

History

There is currently no drug history available for this drug.

Other Information

Lidocaine hydrochloride: acetamide, 2-(diethylamino)-N-(2, 6-dimethylphenyl)-, monohydrochloride has the following structural formula:

Image from Drug Label Content

Lidocaine Hydrochloride Injection, intramuscular for Cardiac Arrhythmias, is a non-pyrogenic, sterile solution prepared from lidocaine hydrochloride, USP and Water for Injection. Lidocaine hydrochloride: C14H22N2O • HCI • H2O has a molecular weight of 288.82.

Each LidoPen® contains 300 mg lidocaine hydrochloride, 3 mg disodium edetate, 3 mg methylparaben, sodium hydroxide in sufficient quantity to adjust pH to 5.2 in 3.0 mL Water for Injection.

Lidopen Manufacturers


  • Meridian Medical Technologies, Inc.
    Lidopen (Lidocaine Hydrochloride) Injection [Meridian Medical Technologies, Inc.]

Login To Your Free Account